Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, April 2000, p. 835-839, Vol. 44, No. 4
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Concentrations of Chloroquine and Malaria Parasites
in Blood in Nigerian Children
Frank P.
Mockenhaupt,1,*
Jürgen
May,1
Yngve
Bergqvist,2
Olusegun G.
Ademowo,3
Peter E.
Olumese,3
Adeyinka G.
Falusi,3
Lars
Großterlinden,1
Christian G.
Meyer,1 and
Ulrich
Bienzle1
Institute of Tropical Medicine and Medical
Faculty Charité, Humboldt-University, Berlin,
Germany1; Dalarna University College,
Borlänge, Sweden2; and
Postgraduate Institute for Medical Research and Training,
University of Ibadan, Ibadan, Nigeria3
Received 6 July 1999/Returned for modification 30 November
1999/Accepted 27 December 1999
 |
ABSTRACT |
Consumption of chloroquine (CQ) and subtherapeutic drug levels in
blood are considered to be widespread in areas where malaria is
endemic. A cross-sectional study was performed with 405 Nigerian children to assess factors associated with the presence of CQ in blood
and to examine correlations of drug levels with malaria parasite
species and densities. Infections with Plasmodium species and parasite densities were determined by microscopy and PCR assays. Whole-blood CQ concentrations were measured by high-performance liquid
chromatography. Plasmodium falciparum, P. malariae, and P. ovale were observed in 80, 16, and
9% of the children, respectively, and CQ was detected in 52% of the
children. CQ concentrations were >17 and <100 nmol/liter in 25% of
the children, 100 to 499 nmol/liter in 14% of the children, and
500
nmol/liter in 13% of the children. Young age, attendance at health
posts, and absence of parasitemia were factors independently associated
with CQ in blood. With increasing concentrations of CQ, the prevalence
of P. falciparum infection and parasite densities
decreased. However, at concentrations corresponding to those usually
attained during regular prophylaxis (
500 nmol/liter), 62% of
children were still harboring P. falciparum parasites. In
contrast, no infection with P. malariae and only one
infection with P. ovale were observed in children with CQ
concentrations of
100 nmol/liter. These data show the high prevalence
of subcurative CQ concentrations in Nigerian children and confirm the
considerable degree of CQ resistance in that country. Subtherapeutic
drug levels are likely to further promote CQ resistance and may impair
the development and maintenance of premunition in areas where malaria
is endemic.
 |
INTRODUCTION |
Chloroquine (CQ) is one of the most
widely consumed drugs (7). In 1988, an estimated 190 tons of
CQ base were used in Africa alone (28). Self-medication,
inadequate dosing, and subtherapeutic levels in blood are frequent and
are believed to be predominant factors that contribute to CQ resistance
in Plasmodium falciparum (25). However, data on
actual CQ levels in residents of areas where malaria is endemic are
scarce. The validity of history taking with respect to antimalarial
drug usage is commonly low (17). Field methods for the
detection of CQ in urine such as the Dill-Glazko test (13)
suffer from poor sensitivity and specificity (21) and cannot
quantify drug concentrations. Nevertheless, tests for detection of CQ
in urine were found to be positive at hospital admission for 32% of
patients in Malawi (17) and in 33% of patients in Zimbabwe
(23). By applying high-performance liquid chromatography (HPLC), CQ was detected in the blood of up to 80% of schoolchildren in
Tanzania, with the drug levels in the majority of children being too
low to eliminate even CQ-sensitive parasites (9). The
whole-blood CQ concentration required to suppress or eliminate P. falciparum is not well recognized. In adults, concentrations in
whole blood of
500 nmol/liter are usually attained during prophylactic intake of 310 mg of chloroquine base/week (20). This concentration, however, may not be sufficient to protect individuals from infection with resistant parasites. In Nigeria, the
efficacy of CQ has continuously declined in recent years, such that the
cure rate at day 7 of treatment is 40% (5).
The present study was performed to assess the prevalence of CQ in whole
blood and whole-blood CQ concentrations among children living in the
area of Ibadan in southwest Nigeria. It aimed at examining patterns of
CQ usage with respect to age, rural or urban residence, and the actual
state of malarial infection. In addition, associations of residual CQ
levels with plasmodial species and parasite densities were looked for.
 |
MATERIALS AND METHODS |
Study population.
The study took place between December 1996 and May 1997 in the city of Ibadan, Nigeria, and the neighboring
village of Abanla. Of 695 subjects enrolled in a survey on
malariological indices (15), CQ and desethylchloroquine
(DCQ) levels were measured in 405 children (222 males and 183 females;
ages, 0.8 to 10 years) for whom parasite densities were known.
Asymptomatic children were recruited from schools and vaccination
programs in Abanla (n = 219) and from schools in Ibadan
(n = 56). Children presenting with fever or a history
of fever were recruited from health posts in Ibadan (n = 130). There were no clinical cases of severe malaria (cerebral
involvement, overt anemia) in this study. Informed consent was obtained
from the parents or guardians of the children included in the study.
Ethical approval was obtained from the Ethical Committee of the
University of Ibadan.
Laboratory examinations.
Blood was collected into EDTA- and
sodium citrate-containing tubes, and the tubes were stored at 4°C.
Malaria parasites were counted microscopically per 100 high-power
(×1,000) fields of Giemsa-stained thick films. In addition, infections
with P. falciparum, P. malariae, and P. ovale were diagnosed by nested PCR assays (22) after
extraction of DNA from blood. Parasite densities were categorized as
"negative," "submicroscopic" (positive PCR result but negative
blood film), "low" (
1 parasite/high-power field [P/F]), and
"moderate" (>1 P/F) (15).
Aliquots of citrate-anticoagulated blood of 100 µl were transferred
onto chromatographic paper (ET 31 Chr; Whatman International, Maidstone, United Kingdom), allowed to dry, and stored at 4°C. The
concentrations of CQ and DCQ were determined by a modified HPLC method
(3). Drug concentrations in duplicate samples were measured
and were corrected for dilution of the blood samples with 10% sodium
citrate. The lower limit of determination was 17 nmol/liter for both CQ
and DCQ.
Statistical analysis.
Frequencies were compared by
2 tests,
2 tests for trend
(
2trend), and Fisher's exact test, as
applicable. In a multivariate analysis, age, study subgroups, and
parasite densities were entered into a logistic regression model to
estimate adjusted odds ratios (ORs) and 95% confidence intervals (95%
CIs) for the presence of CQ in blood. For non-normally distributed
values, Mann-Whitney U tests and Kruskal-Wallis tests were applied.
 |
RESULTS |
Malaria parasites.
Eighty percent (324 of 405) of the children
harbored P. falciparum, while P. malariae was
present in 16% (63 of 405) of the children and P. ovale was
present in 9% (36 of 405) of the children. A total of 62% (252 of
405) of the children were exclusively infected with P. falciparum. Infections with mixtures of the following species were
observed at the indicated rates: P. falciparum plus P. malariae, 9% (36 of 405); P. falciparum plus P. ovale, 2% (9 of 405); and all three organisms, 7% (27 of 405).
Among the infected children, 25% (80 of 324) had submicroscopic
infections, 39% (126 of 324) exhibited low parasite densities (
1
P/F; median, 0.4 P/F; range, 0.01 to 1 P/F), and 36% (118 of 324) had
moderate parasitemias (more than 1 P/F; median, 2.95 P/F; range, 1.1 to 50 P/F). The parasite densities and infecting parasite species differed
among the three subgroups of children (Table
1).
CQ and DCQ levels.
CQ and DCQ were detected in 52% (212 of
405) and 50% (203 of 405) of the children. Concentrations in whole
blood ranged from 17 to 9,100 nmol/liter (median, 106 nmol/liter) for
CQ and from 18 to 5,956 nmol/liter (median, 76 nmol/liter) for DCQ
(Fig. 1). The mean ratio of the CQ
concentration/DCQ concentration was 1.9 (range, 0.3 to 8.4;
n = 199). CQ was more frequently found and concentrations were higher in children attending health posts than in
schoolchildren from Ibadan or in those from the village (Table
2). CQ was especially prevalent in young
children. With increasing age, both the proportion of children with CQ
and the drug concentrations declined. CQ was more frequently detected in noninfected children than in infected ones (68 versus 48%;
2 = 9.8; P = 0.002). Study
subgroups, age, and parasite densities were independently associated
with the presence of CQ in blood (Table 2).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 1.
Cumulative distribution of CQ and DCQ concentrations in
whole blood of Nigerian children (n = 405).
|
|
Drug levels and parasite densities.
CQ concentrations were
below 100 nmol/liter in 25% (103 of 405) of the children, in the range
of 100 to 499 nmol/liter in 14% (57 of 405) of the children, and
500
nmol/liter in 13% (52 of 405) of the children. A total of 87% (167 of
193) of individuals without CQ were infected, whereas infection rates
were 79% (81 of 103), 77% (44 of 57), and 62% (32 of 52) among
individuals with CQ concentrations of <100, 100 to 499, and
500
nmol/liter, respectively (
2trend = 15.3; P < 0.0001). Submicroscopic infections were more frequent in children with CQ (26%; 56 of 212) than among those without
CQ (12%; 24 of 193 [
2 = 11.6; P = 0.0007]). In contrast, the prevalences of low-level parasitemia
(38%; 73 of 193) and moderate-level parasitemia (36%; 70 of 193)
among children without CQ were reduced to 25% (53 of 212 [
2 = 7.2; P = 0.007]) and 23%
(48 of 212 [
2 = 8.4, P = 0.004]),
respectively, in individuals with the drug in their blood.
Correspondingly, with increasing CQ concentrations, the proportion of
submicroscopic infections increased
(
2trend = 13.6; P = 0.0002), and the proportions of low-level
(
2trend = 13.3; P = 0.0003) and moderate-level (
2trend = 8.7, p = 0.003) parasitemias decreased (Fig.
2).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 2.
Percentage of patients with the indicated parasite
densities grouped according to whole-blood CQ concentrations
(n = 405; 2 = 43.9; P < 0.0001).
|
|
CQ and parasite species.
The highest CQ concentration in a
child infected with P. falciparum was 8,578 nmol/liter. The
corresponding levels were 62 nmol/liter in one child infected with
P. malariae and 204 nmol/liter in another child with
P. ovale parasitemia. Despite detectable CQ levels, 74%
(157 of 212), 1.9% (4 of 212), and 1.4% (3 of 212) of the children
harbored P. falciparum, P. malariae, and P. ovale, respectively, whereas 87% (167 of 193), 31% (59 of 193),
and 17% (33 of 193) of the children without CQ in their blood harbored the species, respectively. Adjusted for age groups and study subgroups, CQ in blood was associated with the absence of (i) P. falciparum (OR, 1.9; 95% CI, 1.1 to 3.2; P = 0.03), (ii) P. malariae (OR, 16.6; 95% CI, 5.4 to
50.8; P < 0.0001), and (iii) P. ovale (OR, 9.1; 95% CI, 2.6 to 32.7; P = 0.0007). At a CQ level
of
100 nmol/liter, only one child was infected by a malaria parasite
other than P. falciparum (P. ovale [n = 1 of 109]; CQ concentration, 204 nmol/liter). Likewise,
infections with mixtures of species were frequent in children without
CQ in their blood, (34%; 66 of 193), were uncommon in those with
concentrations of <100 nmol/liter (5%; 5 of 103), and were virtually
absent from those with CQ at levels of
100 nmol/liter (0.9%; 1 of 109).
 |
DISCUSSION |
In this study, 52% of children had blood CQ levels above the
lower limit of detection, and 80% were infected with P. falciparum. Taking into account the long terminal half-life of
chloroquine of approximately 2 to 3 weeks (26) and the high
rate of transmission of malaria parasites in the study area, it can be
assumed that most of the P. falciparum strains in this
population have been or are currently exposed to drug concentrations
that are inadequate to eliminate the parasites. This constellation,
namely, intense parasite transmission and the widespread presence of
subcurative drug levels in blood, most likely constitutes a
predisposing environment for the selection and spread of resistant
P. falciparum strains (25). As resistance
gradually expands and intensifies, it is also likely that the drug is
taken more frequently and at higher doses. As a consequence, more
intense drug pressure will then select for more resistant parasites.
The elimination of parasites is thought to be a function of both the
peak drug concentration and the time span during which inhibitory
levels are present (10, 19). In this cross-sectional study,
a given CQ concentration could reflect recent intake or consumption of
a higher dosage a longer time ago. Since the half-life of DCQ is longer
than that of CQ (8), the relatively high mean ratio of the
CQ concentration/DCQ concentration suggests that the majority of
children had taken the drug recently before the blood collection. At
concentrations that have been shown to be attained in whole blood
during long-term chemoprophylaxis (
500 nmol/liter) (20),
62% of children were found to be infected with P. falciparum in the present study. This closely matches the
treatment failure rate of 60% of a recent clinical trial in Ibadan
(5) and confirms the serious extent of CQ resistance in this area.
With increasing CQ concentrations, a shift from microscopically visible
parasitemia toward submicroscopic infections and an absence of
parasites was observed. In areas of holoendemicity, a certain
percentage of actual infections can be detected only by PCR (12,
15). These submicroscopic infections may result from parasites
that could not be cleared by drug or the host defense system but that
remained present at a low level of multiplication from which they could recrudesce.
CQ caused a similar reduction in the proportions of low- and
moderate-level parasitemias. It should be expected that the drug more
easily eradicates smaller numbers than larger numbers of parasites. The
effect of CQ on parasite numbers is not a linear one. Immunity, drug
resistance, and fluctuations in parasite densities may be involved as well.
Independent of age, CQ was more frequently found in the blood of urban
children than in the blood of children originating from the village,
consistent with easier access to antimalarial agents in urban areas
(18). The large number of blood specimens positive for CQ
and the high drug levels in blood among children attending health posts
reflect the common patterns of treatment at home and self-medication.
This high rate of presumptive treatment of fever with CQ prior to the
parasitological diagnosis of malaria, in addition to the effect of
presumptive treatment in selecting for resistant parasite strains, can
be a reason for additional CQ toxicity in such settings. Also, CQ
consumption may partly explain the differences in parasitological
indices between the three subgroups of children. For example, the
lowest rate of use of CQ as well as the highest rate of infection, the
highest parasite densities, and the highest prevalence of mixed species
infections with mixtures of species, was observed among children from
the rural village.
In comparison to data for Tanzanian schoolchildren assessed in 1988 (9), CQ levels in our study group were essentially higher.
In Tanzania, only 9 and 2% of children had concentrations in whole
blood of >100 and >500 nmol/liter, respectively, whereas 27 and 13%
of the children in the present study had such concentrations, respectively. This could result from geographical differences in the
rates of CQ intake, but it may also indicate the progression of CQ
resistance in Africa and, subsequently, increasing rates of drug use
during the last decade.
Age was a major determinant of blood CQ levels, as the highest
prevalences and concentrations were seen among the youngest children.
This age distribution of parasite prevalence and CQ concentration
corresponds to the higher incidence and severity of malaria in that age
group (11). It has been shown that, at equal dosages per
body weight, plasma CQ concentrations are lower in young children than
in older children and adults (14). Higher concentrations of
CQ in young children could indicate the intake of fixed doses of the
drug, e.g., one tablet in case of a fever, irrespective of age or
weight. Recently, we have shown that the prevalence of P. falciparum, P. malariae, and P. ovale
increases with age in this particular population, with the last two
species being rare in children younger than 5 years of age
(15). The common use of CQ, especially by young children, is
likely to be responsible for this finding. Likewise, P. malariae and P. ovale infections, and thus infections
with two and three species, were almost absent from children whose
blood contained CQ at
100 nmol/liter. It has been suggested that
infections with parasite strains other than P. falciparum
could act as natural vaccines, preventing severe manifestations of
P. falciparum infections (27). If that finding holds true, presumptive CQ treatment or prophylaxis might increase the
risk for subsequent severe P. falciparum malaria.
A couple of other observations argue against the nonjudicious use of
CQ. In infants, an increased rate of clinical malaria has been observed
after the discontinuation of CQ chemoprophylaxis, indicating an
impaired development or maintenance of immune protection during the
period of chemoprophylaxis (16). Furthermore, asymptomatic, polyclonal P. falciparum infections appear to protect
individuals against clinical disease from newly acquired infections
(6). Correspondingly, mono- or oligoclonal P. falciparum infections may increase the risk of succeeding clinical
malaria (1). Recent data indicate that the multiplicity of
P. falciparum infections decreases in the presence of
subcurative CQ levels (2). Long-lasting or recurrent CQ
levels in blood could therefore be disadvantageous because of the
elimination of persisting polyclonal infections that might be necessary
to maintain protective immunity in regions where malaria is endemic.
The absence of severe malaria in the group of children with a high
prevalence of residual CQ levels examined in the present study is
seemingly in contrast to the hypothesis presented above. However, in a
cross-sectional study, only a few clinical episodes and even fewer
cases of severe malaria can be expected. This is particularly true for
the children recruited at schools and vaccination programs. This study
was not designed to provide information on the incidence of clinical
malaria once CQ levels would have declined. Longitudinal studies may
help to understand the complex interactions between the multiplicity of
P. falciparum infections, immunity, and antimalarial drug
use in residents of regions where malaria is endemic.
Due to the expansion of CQ resistance, the rate of mortality from
malaria is increasing in Africa (4, 24). The widespread use
of the drug, the large proportion of individuals with nonparasiticidal drug levels in their blood, and the almost uninhibited transmission are
prerequisites for the further emergence of CQ resistance. The efficacy
of CQ can now be envisaged to decline even more. So far, a drug as
affordable and safe as CQ is not available. Consequently, to contain
its efficacy in those areas that are not yet affected by CQ resistance,
a specific diagnosis of malaria should precede specific treatment.
 |
ACKNOWLEDGMENTS |
This study was supported by the Volkswagen Foundation and by a
grant from the Sonnenfeld Foundation to F.P.M.
We thank Lars Rombo for constructive comments on the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institut
für Tropenmedizin, Spandauer Damm 130, 14050 Berlin, Germany.
Phone: 49-30-30116-750. Fax: 49-30-30116-888. E-mail:
frank.mockenhaupt{at}charite.de.
 |
REFERENCES |
| 1.
|
al-Yaman, F.,
B. Genton,
J. C. Reeder,
R. F. Anders,
T. Smith, and M. P. Alpers.
1997.
Reduced risk of clinical malaria in children infected with multiple clones of Plasmodium falciparum in a highly endemic area: a prospective community study.
Trans. R. Soc. Trop. Med. Hyg.
91:602-605[CrossRef][Medline].
|
| 2.
|
Beck, H. P.,
I. Felger,
P. Vounatsou,
M. Tanner,
P. Alonso, and C. Menendez.
1999.
Effect of iron supplementation and malaria prophylaxis in infants on Plasmodium falciparum genotypes and multiplicity of infection.
Trans. R. Soc. Trop. Med. Hyg.
93(Suppl. I):41-45.
|
| 3.
|
Bergqvist, Y., and M. Frisk-Holmberg.
1980.
Sensitive method for the determination of chloroquine and its metabolite desethylchloroquine in human plasma and urine by high performance liquid chromatography.
J. Chromatogr.
221:119-227[Medline].
|
| 4.
|
Carme, B.,
B. Yombi,
J. C. Bouquerty,
H. Plassard,
S. Nzingnula,
J. Senga, and I. Akani.
1992.
Child morbidity and mortality due to cerebral malaria in Brazzaville, Congo. A retrospective and prospective hospital-based study.
Trop. Med. Parasitol.
43:173-176[Medline].
|
| 5.
|
Falade, C. O.,
L. A. Salako,
A. Sowunmi,
A. M. Oduola, and P. Larcier.
1997.
Comparative efficacy of halofantrine, chloroquine and sulfadoxine-pyrimethamine for treatment of acute uncomplicated falciparum malaria in Nigerian children.
Trans. R. Soc. Trop. Med. Hyg.
91:58-62[CrossRef][Medline].
|
| 6.
|
Färnert, A.,
I. Rooth,
Å. Svensson,
G. Snounou, and A. Bjorkman.
1999.
Complexity of Plasmodium falciparum infections is consistent over time and protects against clinical disease in Tanzanian children.
J. Infect. Dis.
179:989-995[CrossRef][Medline].
|
| 7.
|
Foster, S.
1994.
Economic prospects for a new antimalarial drug.
Trans. R. Soc. Trop. Med. Hyg.
88(Suppl.):55-56[Medline].
|
| 8.
|
Gustafsson, L. L.,
B. Lindstrom,
A. Grahnen, and G. Alvan.
1987.
Chloroquine excretion following malaria prophylaxis.
Br. J. Clin. Pharmacol.
24:221-224[Medline].
|
| 9.
|
Hellgren, U.,
Ö. Ericsson,
C. M. Kihamia, and L. Rombo.
1994.
Malaria parasites and chloroquine concentrations in Tanzanian schoolchildren.
Trop. Med. Parasitol.
45:293-297[Medline].
|
| 10.
|
Hellgren, U.,
C. M. Kihamia,
L. F. Mahikwano,
A. Björkman,
Ö. Eriksson, and L. Rombo.
1989.
Response of Plasmodium falciparum to chloroquine treatment: relation of whole blood concentrations of chloroquine and desethylchloroquine.
Bull. W. H. O.
67:197-202[Medline].
|
| 11.
|
Imbert, P.,
I. Sartelet,
C. Rogier,
S. Ka,
G. Baujat, and D. Candito.
1997.
Severe malaria among children in a low seasonal transmission area, Dakar, Senegal: influence of age on clinical presentation.
Trans. R. Soc. Trop. Med. Hyg.
91:22-24[CrossRef][Medline].
|
| 12.
|
Jarra, W., and G. Snounou.
1998.
Only viable parasites are detected by PCR following clearance of rodent malarial infections by drug treatment or immune responses.
Infect. Immun.
66:3783-3787[Abstract/Free Full Text].
|
| 13.
|
Lelijveld, J., and H. Kortmann.
1979.
The eosin colour test of Dill and Glazko: a simple field test to detect chloroquine in urine.
Bull. W. H. O.
42:477-479.
|
| 14.
|
Maitland, K.,
T. N. Williams,
B. M. Kotecka,
M. D. Edstein, and K. H. Rieckmann.
1997.
Plasma chloroquine concentrations in young and older malaria patients treated with chloroquine.
Acta Trop.
66:155-161[Medline].
|
| 15.
|
May, J.,
F. P. Mockenhaupt,
O. G. Ademowo,
A. G. Falusi,
P. E. Olumese,
U. Bienzle, and C. G. Meyer.
1999.
High rate of mixed malarial infections and submicroscopic parasitemia in South West Nigeria.
Am. J. Trop. Med. Hyg.
61:339-343[Abstract].
|
| 16.
|
Menendez, C.,
E. Kahigwa,
R. Hirt,
P. Vounatsou,
J. J. Aponte,
F. Font,
C. J. Acosta,
D. M. Schellenberg,
C. M. Galindo,
J. Kimario,
H. Urassa,
B. Brabin,
T. A. Smith,
A. Y. Kitua,
M. Tanner, and P. L. Alonso.
1997.
Randomized placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
Lancet
350:844-850[CrossRef][Medline].
|
| 17.
|
Nwanyanwu, O. C.,
S. C. Redd,
C. Ziba,
S. P. Luby,
D. L. Mount,
C. Franco,
Y. Nyasulu, and L. Chitsulo.
1996.
Validity of mother's history regarding antimalarial drug use in Malawian children under five years old.
Trans. R. Soc. Trop. Med. Hyg.
90:66-68[Medline].
|
| 18.
|
Plowe, C. V.,
A. Djimde,
T. E. Wellems,
S. Diop,
B. Kouriba, and O. K. Doumbo.
1996.
Community pyrimethamine-sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance.
Am. J. Trop. Med. Hyg.
55:467-471.
|
| 19.
|
Richards, W. H. G., and B. K. Maples.
1979.
Studies on P. falciparum in continuous cultivation. The effect of chloroquine and pyrimethamine on parasite growth and viability.
Ann. Trop. Med. Parasitol.
73:99-108[Medline].
|
| 20.
|
Rombo, L.,
Y. Bergqvist, and U. Hellgren.
1987.
Chloroquine and desethylchloroquine concentrations during regular long-term malaria prophylaxis.
Bull. W. H. O.
65:879-883[Medline].
|
| 21.
|
Schwick, P.,
T. A. Eggelte,
F. Hess,
T. T. Tueumuna,
D. Payne,
H. D. Nothdurft,
F. von Sonnenburg, and T. Löscher.
1998.
Sensitive ELISA dipstick test for the detection of chloroquine in urine under field conditions.
Trop. Med. Int. Health
3:828-832[Medline].
|
| 22.
|
Snounou, G.,
S. Viriyakosol,
X. P. Zhu,
W. Jarra,
L. Pinheiro,
V. E. do Rosario,
S. Thaithong, and K. N. Brown.
1993.
High sensitivity of detection of human malaria parasites by use of nested polymerase chain reaction.
Mol. Biochem. Parasitol.
61:315-320[CrossRef][Medline].
|
| 23.
|
Taylor, H. G.,
C. M. Stein, and G. Jongeling.
1988.
Drug use before hospital admission in Zimbabwe.
Eur. J. Clin. Pharmacol.
34:87-90[Medline].
|
| 24.
|
Trape, J. F.,
G. Pison,
M. P. Preziosi,
C. Enel,
A. Desgrees du Lou,
V. Delaunay,
B. Samb,
E. Lagarde,
J. F. Molez, and F. Simondon.
1998.
Impact of chloroquine resistance on malaria mortality.
C. R. Acad. Sci. III
321:689-697[Medline].
|
| 25.
|
Wernsdorfer, W. H.
1991.
The development and spread of drug-resistant malaria.
Parasitol. Today
7:297-303[CrossRef][Medline].
|
| 26.
|
Wetsteyn, J. C.,
P. J. De Vries,
B. Oosterhuis, and C. J. van Boxtel.
1995.
The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis.
Br. J. Clin. Pharmacol.
39:696-699[Medline].
|
| 27.
|
Williams, T. N.,
K. Maitland,
S. Bennett,
M. Ganczakowski,
T. E. Peto,
C. I. Newbold,
D. K. Bowden,
D. J. Weatherall, and J. B. Clegg.
1996.
High incidence of malaria in alpha-thalassaemic children.
Nature
383:522-525[CrossRef][Medline].
|
| 28.
|
World Health Organization.
1990.
Practical chemotherapy of malaria. WHO Technical Report Series No. 805.
World Health Organization, Geneva, Switzerland.
|
Antimicrobial Agents and Chemotherapy, April 2000, p. 835-839, Vol. 44, No. 4
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.